International Stem Cell posted a net loss of $71,000 for the quarter ended June 30, 2026, versus net income of $129,000 a year earlier.
Product sales rose 9% to $2.68 million, while cost of sales climbed 31% to $1.22 million.
General and administrative expenses increased 17% to $1.06 million, driven by higher legal and consulting costs tied to strategic activities.
Research and development spending edged down 4% to $155,000, while selling and marketing costs slipped 3% to $276,000.
The company reiterated it has no revenue from therapeutic product development and cited substantial doubt about its ability to continue as a going concern.
ISCO•
